 spark therapeutics inc nasdaqonce rating lowered to sell at zacks investment research  bnb daily daily ratings  news for spark therapeutics inc complete the form below to receive the latest headlines and analysts recommendationsfor spark therapeutics inc with our free daily email newsletter follow bnbdailynews recent posts fmr llc sells  shares of agree realty corporation adc national retail properties nnn stake reduced by fmr llc fmr llc sells  shares of xencor inc xncr somewhat positive news coverage likely to affect rait financial trust nyseras stock price chris malley sells  shares of carclo plc car stock condor hospitality trust inc nasdaqcdor expected to post quarterly sales of  million zacks investment research downgrades achillion pharmaceuticals inc achn to sell on track innovations ltd nasdaqotiv earns buy rating from analysts at lake street capital spark therapeutics inc nasdaqonce rating lowered to sell at zacks investment research united services automobile association has  position in masimo corporation nasdaqmasi bright horizons family solutions inc nysebfam position maintained by united services automobile association chemed corp nyseche stake cut by united services automobile association mdc holdings inc nysemdc shares bought by oppenheimerfunds inc oppenheimerfunds inc buys  shares of boyd gaming corporation nysebyd oppenheimerfunds inc boosts stake in ncr corporation nysencr principal financial group inc buys  shares of armada hoffler properties inc nyseahh tilly’s nysetlys given news impact score of  triangle capital corporation nysetcap getting positive media coverage analysis finds sasol nysessl earning somewhat favorable news coverage report shows seaspine holdings corporation nasdaqspne getting favorable press coverage analysis shows spark therapeutics inc nasdaqonce rating lowered to sell at zacks investment research posted by dan jones on jul th   no comments spark therapeutics inc nasdaqonce was downgraded by zacks investment research from a “hold” rating to a “sell” rating in a research note issued to investors on wednesday july th according to zacks “spark therapeutics inc offers gene therapy the company’s product candidate consist of spkrpe spkchm spkfix which are in different clinical phases for the treatment of additional blinding conditions hematologic disorders and neurodegenerative diseases spark therapeutics inc is based in philadelphia pennsylvania “ a number of other analysts have also recently issued reports on once ubs ag assumed coverage on spark therapeutics in a report on wednesday march th they set a “buy” rating and a  target price for the company jefferies group llc assumed coverage on spark therapeutics in a report on monday july th they set a “buy” rating and a  target price for the company valuengine upgraded spark therapeutics from a “sell” rating to a “hold” rating in a report on tuesday june th bidaskclub upgraded spark therapeutics from a “sell” rating to a “hold” rating in a report on thursday june nd finally wedbush reiterated an “underperform” rating and set a  target price on shares of spark therapeutics in a report on wednesday may th one analyst has rated the stock with a sell rating four have issued a hold rating and ten have issued a buy rating to the stock spark therapeutics has an average rating of “buy” and an average price target of  get spark therapeutics inc alerts spark therapeutics once traded up  during midday trading on wednesday hitting   shares of the stock were exchanged the stock’s market cap is  billion the firm has a day moving average price of  and a day moving average price of  spark therapeutics has a one year low of  and a one year high of  spark therapeutics nasdaqonce last posted its quarterly earnings results on tuesday may th the biotechnology company reported  eps for the quarter missing the consensus estimate of  by  the business had revenue of  million during the quarter compared to analysts’ expectations of  million spark therapeutics had a negative net margin of  and a negative return on equity of  the firm’s quarterly revenue was down  compared to the same quarter last year during the same quarter last year the firm earned  eps on average equities research analysts anticipate that spark therapeutics will post  eps for the current fiscal year trademark violation notice this report was first posted by bnb daily and is owned by of bnb daily if you are reading this report on another site it was stolen and republished in violation of us  international trademark  copyright law the original version of this report can be accessed at httpswwwbaseballnewsblogcomzacksinvestmentresearchdowngradessparktherapeuticsincnasdaqoncetosellupdatedhtml in other news director anand mehra sold  shares of the stock in a transaction on wednesday june st the stock was sold at an average price of  for a total value of  the transaction was disclosed in a legal filing with the securities  exchange commission which is available at this hyperlink also cfo stephen w webster sold  shares of the stock in a transaction on tuesday april th the stock was sold at an average price of  for a total value of  following the completion of the transaction the chief financial officer now directly owns  shares of the company’s stock valued at approximately  the disclosure for this sale can be found here over the last three months insiders have sold  shares of company stock worth  corporate insiders own  of the company’s stock several hedge funds and other institutional investors have recently added to or reduced their stakes in the company highbridge capital management llc acquired a new position in spark therapeutics during the first quarter valued at about  kcg holdings inc boosted its position in shares of spark therapeutics by  in the first quarter kcg holdings inc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter state board of administration of florida retirement system boosted its position in shares of spark therapeutics by  in the fourth quarter state board of administration of florida retirement system now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter cornerstone capital management holdings llc purchased a new position in shares of spark therapeutics during the first quarter valued at  finally american international group inc boosted its position in shares of spark therapeutics by  in the first quarter american international group inc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter  of the stock is owned by institutional investors spark therapeutics company profile spark therapeutics inc is a gene therapy company the company focuses on treating orphan diseases it has a pipeline of product candidates targeting multiple rare blinding conditions hematologic disorders and neurodegenerative diseases its pipeline includes a product candidate targeting choroideremia chm which is in a phase iii clinical trial and a product candidate for hemophilia a which is in a phase iii clinical trial get a free copy of the zacks research report on spark therapeutics once for more information about research offerings from zacks investment research visit zackscom receive news  ratings for spark therapeutics inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for spark therapeutics inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website spark therapeutics once now covered by bernstein with  target last week take two interactive software ttwo analysts  bibey post trending stock news penny stock news market news stock news spark therapeutics once now covered by bernstein with  target last week take two interactive software ttwo analysts july    by marie mckinney among  analysts covering taketwo interactive software nasdaqttwo  have buy rating  sell and  hold therefore  are positive taketwo interactive software had  analyst reports since july   according to sratingsintel the stock of take two interactive software inc nasdaqttwo earned “buy” rating by stifel nicolaus on monday july  the firm has “buy” rating by brean capital given on tuesday august  the rating was upgraded by btig research to “buy” on thursday september  bmo capital markets initiated the stock with “outperform” rating in wednesday april  report on tuesday august  the stock rating was maintained by piper jaffray with “overweight” as per tuesday august  the company rating was maintained by jefferies as per friday july  the company rating was maintained by cowen  co the rating was maintained by stifel nicolaus with “buy” on wednesday january  the stock of take two interactive software inc nasdaqttwo has “neutral” rating given on thursday february  by wedbush the stock has “buy” rating by m partners on thursday february  see take two interactive software inc nasdaqttwo latest ratings  broker m partners rating buy  broker cowen  co rating buy new target  maintain broker stifel nicolaus rating buy new target  maintain broker jefferies rating buy new target  maintain broker piper jaffray rating buy new target  maintain broker hilliard lyons rating sell downgrade among  analysts covering spark therapeutics nasdaqonce  have buy rating  sell and  hold therefore  are positive spark therapeutics has  highest and  lowest target ’s average target is  below currents  stock price spark therapeutics had  analyst reports since august   according to sratingsintel the rating was initiated by jefferies on thursday june  with “hold” the rating was initiated by evercore on tuesday april  with “buy” the rating was maintained by stifel nicolaus with “buy” on monday june  the stock of spark therapeutics inc nasdaqonce has “hold” rating given on friday august  by zacks the stock has “buy” rating by jefferies on tuesday july  chardan capital markets maintained spark therapeutics inc nasdaqonce on thursday july  with “hold” rating on friday september  the stock rating was initiated by stifel nicolaus with “buy” as per thursday june  the company rating was maintained by cantor fitzgerald on wednesday december  the stock rating was initiated by chardan capital markets with “neutral” the rating was maintained by roth capital with “buy” on monday october  taketwo interactive software inc is a developer publisher and marketer of entertainment for clients around the world the company has market cap of  billion the firm develops and publishes products through its labels rockstar games and k it has a  pe ratio it operates through publishing segment about  shares traded take two interactive software inc nasdaqttwo has risen  since july   and is uptrending it has outperformed by  the sp since february   it had  insider buys and  selling transactions for  million activity sheresky michael sold  worth of take two interactive software inc nasdaqttwo on monday february  emerson daniel p had sold  shares worth  the insider zelnick strauss sold  shares worth  million slatoff karl had sold  shares worth m on tuesday april  investors sentiment increased to  in q  its up  from  in q it increased as  investors sold take two interactive software inc shares while  reduced holdings  funds opened positions while  raised stakes  million shares or  more from  million shares in q were reported stifel fin corporation invested in  shares or  of the stock federated investors pa invested  in take two interactive software inc nasdaqttwo susquehanna intll grp ltd liability partnership has invested  in take two interactive software inc nasdaqttwo barclays public ltd company invested in  shares eagle asset invested in m shares or  of the stock ameriprise has invested  in take two interactive software inc nasdaqttwo bank of montreal can has  shares  were accumulated by principal financial group inc incorporated cantab capital ptnrs llp has invested  of its portfolio in take two interactive software inc nasdaqttwo moreover rothschild asset mngmt has  invested in take two interactive software inc nasdaqttwo for  shares ls inv advisors ltd liability corporation stated it has  shares northern trust stated it has  million shares creative planning stated it has  of its portfolio in take two interactive software inc nasdaqttwo walleye trading limited liability has  invested in take two interactive software inc nasdaqttwo for  shares kcg inc accumulated  shares spark therapeutics inc is a gene therapy company the company has market cap of  billion the firm focuses on treating orphan diseases it currently has negative earnings it has a pipeline of product candidates targeting multiple rare blinding conditions hematologic disorders and neurodegenerative diseases analysts await spark therapeutics inc nasdaqonce to report earnings on august  they expect  eps down  or  from last year’s  per share after  actual eps reported by spark therapeutics inc for the previous quarter wall street now forecasts  negative eps growth the stock increased  or  during the last trading session reaching  about shares traded spark therapeutics inc nasdaqonce has risen  since july   and is uptrending it has underperformed by  the sp by marie mckinney echostar corporationreceive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with our free daily email newsletter free newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter recent posts evolent health evh at  forms top granite construction gva’s sentiment is  parker drilling company pkd reaches  week low bioscrip bios shorts lowered by  genesee valley trust company has cut the priceline group pcln holding by  biocorrx bicx si decreased by  matthew  management has lowered scripps networks interactive sni position by  million rand wealth has increased automatic data processing in adp holding by  million fonar fonr reaches  after  down move mgic investment corp mtg had  analysts last week resources connection inc recn reaches  after  up move acadian timber tseadn had  bullish analysts green square capital has lifted its att com t position bbt capital management has upped amc networks call amcx stake by  american capital management cut its verint systems vrnt holding deutsche lufthansa ag etrlha covered by  bullish analysts last week lowe brockenbrough  company has cut by  million its cvs health com cvs position  analysts covering compass diversified holdings codi davidson d a  company lifted amgen amgn stake last week orion group holdings orn analysts  copyright  bibey post inc  bibeypostcom       about  our team  contact contact us – spark therapeutics we arespark our scientificplatform  programs « back our scientificplatform  programs about gene therapy patients families healthcareprofessionals investors media « back investors media media investors overview stock information stock quote  chart historical stock lookup stock calculator analyst coverage press releases events investor presentations corporate governance corporate compliance highlights management team board of directors committee composition annual meeting financial information sec filings shareholder services investor contacts join thespark team contact us for partners bizdevsparktxcom for patients and families patientssparktxcom for healthcare professionals medinfosparktxcom for employment opportunities careerssparktxcom for media communicationssparktxcom for investors investorsparktxcom for general inquiries infosparktxcom sparktx    if you are interested in unsubscribing for updates please click here stay up to date on our progress sign up to receive information from spark therapeutics first name  last name  email address  state nonealabamaalaskaamerican samoaarizonaarkansascaliforniacoloradoconnecticutdelawaredistrict of columbiafloridageorgiaguamhawaiiidahoillinoisindianaiowakansaskentuckylouisianamainemarshall islandsmarylandmassachusettsmichiganminnesotamississippimissourimontananebraskanevadanew hampshirenew jerseynew mexiconew yorknorth carolinanorth dakotanorthern marianas islandsohiooklahomaoregonpalaupennsylvaniapuerto ricorhode islandsouth carolinasouth dakotatennesseetexasutahvermontvirgin islandsvirginiawashingtonwest virginiawisconsinwyoming country  selectafghanistanaland islandsalbaniaalgeriaamerican samoaandorraangolaanguillaantarcticaantigua and barbudaargentinaarmeniaarubaaustraliaaustriaazerbaijanbahamasbahrainbangladeshbarbadosbelarusbelgiumbelizebeninbermudabhutanboliviabosnia and herzegovinabotswanabouvet islandbrazilbritish indian ocean territorybritish virgin islandsbruneibulgariaburkina fasoburundicambodiacamerooncanadacape verdecaribbean netherlandscayman islandscentral african republicchadchilechinachristmas islandcocos keeling islandscolombiacomoroscongo brazzavillecongo kinshasacook islandscosta ricacroatiacubacuraçaocyprusczech republicdenmarkdjiboutidominicadominican republicecuadoregyptel salvadorequatorial guineaeritreaestoniaethiopiafalkland islandsfaroe islandsfijifinlandfrancefrench guianafrench polynesiafrench southern territoriesgabongambiageorgiagermanyghanagibraltargreecegreenlandgrenadaguadeloupeguamguatemalaguernseyguineaguineabissauguyanahaitiheard island and mcdonaldhondurashong kong sar chinahungaryicelandindiaindonesiairaniraqirelandisle of manisraelitalyivory coastjamaicajapanjerseyjordankazakhstankenyakiribatikuwaitkyrgyzstanlaoslatvialebanonlesotholiberialibyaliechtensteinlithuanialuxembourgmacao sar chinamacedoniamadagascarmalawimalaysiamaldivesmalimaltamarshall islandsmartiniquemauritaniamauritiusmayottemexicomicronesiamoldovamonacomongoliamontenegromontserratmoroccomozambiquemyanmarnamibianaurunepalnetherlandsnetherlands antillesnew caledonianew zealandnicaraguanigernigerianiuenorfolk islandnorthern mariana islandsnorth koreanorwayomanpakistanpalaupalestinian territorypanamapapua new guineaparaguayperuphilippinespitcairnpolandportugalpuerto ricoqatarreunionromaniarussiarwandasaint barthélemysaint helenasaint kitts and nevissaint luciasaint martin french partsaint pierre and miquelonsaint vincent and thesamoasan marinosao tome and principesaudi arabiasenegalserbiaseychellessierra leonesingaporesint maartenslovakiasloveniasolomon islandssomaliasouth africasouth georgia and thesouth koreasouth sudanspainsri lankasudansurinamesvalbard and jan mayenswazilandswedenswitzerlandsyriataiwantajikistantanzaniathailandtimorlestetogotokelautongatrinidad and tobagotunisiaturkeyturkmenistanturks and caicos islandstuvaluus virgin islandsugandaukraineunited arab emiratesunited kingdomunited statesunited states minor outlyinguruguayuzbekistanvanuatuvaticanvenezuelavietnamwallis and futunawestern saharayemenzambiazimbabwe i am a  patientcaregiverhealthcare professionalmember of the media about what diseases are you interested in receiving more information  inherited retinal diseases irdshemophilia and other bloodclotting disordersneurodegenerative diseases additional comments or questions terms of use agreement  i agree to the statement below and have read and understand the legal disclaimer and privacy policy i authorize spark therapeutics inc and companies working with spark to contact me by mail email fax telephone call and text message including autodialed and prerecorded calls and messages for marketing purposes or otherwise provide me with information about sparks products services and programs or other topics of interest conduct market research or otherwise ask me about my experience with or thoughts about such topics i understand and agree that any information that i provide may be used by spark to help develop new products services and programs i understand that my consent is not required as a condition of purchasing or receiving any goods or services from spark i understand that i may revoke this authorization and choose not to receive information from spark by clicking the unsubscribe link at the top of this page or through a link provided in emails i receive from spark spark therapeutics inc  market street philadelphia pa  phone sparktx      spark therapeutics inc contact us privacy policy terms of use spark therapeutics once now covered by bernstein with  target last week take two interactive software ttwo analysts  bibey post trending stock news penny stock news market news stock news spark therapeutics once now covered by bernstein with  target last week take two interactive software ttwo analysts july    by marie mckinney among  analysts covering taketwo interactive software nasdaqttwo  have buy rating  sell and  hold therefore  are positive taketwo interactive software had  analyst reports since july   according to sratingsintel the stock of take two interactive software inc nasdaqttwo earned “buy” rating by stifel nicolaus on monday july  the firm has “buy” rating by brean capital given on tuesday august  the rating was upgraded by btig research to “buy” on thursday september  bmo capital markets initiated the stock with “outperform” rating in wednesday april  report on tuesday august  the stock rating was maintained by piper jaffray with “overweight” as per tuesday august  the company rating was maintained by jefferies as per friday july  the company rating was maintained by cowen  co the rating was maintained by stifel nicolaus with “buy” on wednesday january  the stock of take two interactive software inc nasdaqttwo has “neutral” rating given on thursday february  by wedbush the stock has “buy” rating by m partners on thursday february  see take two interactive software inc nasdaqttwo latest ratings  broker m partners rating buy  broker cowen  co rating buy new target  maintain broker stifel nicolaus rating buy new target  maintain broker jefferies rating buy new target  maintain broker piper jaffray rating buy new target  maintain broker hilliard lyons rating sell downgrade among  analysts covering spark therapeutics nasdaqonce  have buy rating  sell and  hold therefore  are positive spark therapeutics has  highest and  lowest target ’s average target is  below currents  stock price spark therapeutics had  analyst reports since august   according to sratingsintel the rating was initiated by jefferies on thursday june  with “hold” the rating was initiated by evercore on tuesday april  with “buy” the rating was maintained by stifel nicolaus with “buy” on monday june  the stock of spark therapeutics inc nasdaqonce has “hold” rating given on friday august  by zacks the stock has “buy” rating by jefferies on tuesday july  chardan capital markets maintained spark therapeutics inc nasdaqonce on thursday july  with “hold” rating on friday september  the stock rating was initiated by stifel nicolaus with “buy” as per thursday june  the company rating was maintained by cantor fitzgerald on wednesday december  the stock rating was initiated by chardan capital markets with “neutral” the rating was maintained by roth capital with “buy” on monday october  taketwo interactive software inc is a developer publisher and marketer of entertainment for clients around the world the company has market cap of  billion the firm develops and publishes products through its labels rockstar games and k it has a  pe ratio it operates through publishing segment about  shares traded take two interactive software inc nasdaqttwo has risen  since july   and is uptrending it has outperformed by  the sp since february   it had  insider buys and  selling transactions for  million activity sheresky michael sold  worth of take two interactive software inc nasdaqttwo on monday february  emerson daniel p had sold  shares worth  the insider zelnick strauss sold  shares worth  million slatoff karl had sold  shares worth m on tuesday april  investors sentiment increased to  in q  its up  from  in q it increased as  investors sold take two interactive software inc shares while  reduced holdings  funds opened positions while  raised stakes  million shares or  more from  million shares in q were reported stifel fin corporation invested in  shares or  of the stock federated investors pa invested  in take two interactive software inc nasdaqttwo susquehanna intll grp ltd liability partnership has invested  in take two interactive software inc nasdaqttwo barclays public ltd company invested in  shares eagle asset invested in m shares or  of the stock ameriprise has invested  in take two interactive software inc nasdaqttwo bank of montreal can has  shares  were accumulated by principal financial group inc incorporated cantab capital ptnrs llp has invested  of its portfolio in take two interactive software inc nasdaqttwo moreover rothschild asset mngmt has  invested in take two interactive software inc nasdaqttwo for  shares ls inv advisors ltd liability corporation stated it has  shares northern trust stated it has  million shares creative planning stated it has  of its portfolio in take two interactive software inc nasdaqttwo walleye trading limited liability has  invested in take two interactive software inc nasdaqttwo for  shares kcg inc accumulated  shares spark therapeutics inc is a gene therapy company the company has market cap of  billion the firm focuses on treating orphan diseases it currently has negative earnings it has a pipeline of product candidates targeting multiple rare blinding conditions hematologic disorders and neurodegenerative diseases analysts await spark therapeutics inc nasdaqonce to report earnings on august  they expect  eps down  or  from last year’s  per share after  actual eps reported by spark therapeutics inc for the previous quarter wall street now forecasts  negative eps growth the stock increased  or  during the last trading session reaching  about shares traded spark therapeutics inc nasdaqonce has risen  since july   and is uptrending it has underperformed by  the sp by marie mckinney echostar corporationreceive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with our free daily email newsletter free newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter recent posts evolent health evh at  forms top granite construction gva’s sentiment is  parker drilling company pkd reaches  week low bioscrip bios shorts lowered by  genesee valley trust company has cut the priceline group pcln holding by  biocorrx bicx si decreased by  matthew  management has lowered scripps networks interactive sni position by  million rand wealth has increased automatic data processing in adp holding by  million fonar fonr reaches  after  down move mgic investment corp mtg had  analysts last week resources connection inc recn reaches  after  up move acadian timber tseadn had  bullish analysts green square capital has lifted its att com t position bbt capital management has upped amc networks call amcx stake by  american capital management cut its verint systems vrnt holding deutsche lufthansa ag etrlha covered by  bullish analysts last week lowe brockenbrough  company has cut by  million its cvs health com cvs position  analysts covering compass diversified holdings codi davidson d a  company lifted amgen amgn stake last week orion group holdings orn analysts  copyright  bibey post inc  bibeypostcom       about  our team  contact spark therapeutics inc onceo company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile spark therapeutics inc onceo related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse onceo on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description spark therapeutics inc spark incorporated on march   is a gene therapy company the company focuses on treating orphan diseases it has a pipeline of product candidates targeting multiple rare blinding conditions hematologic disorders and neurodegenerative diseases its pipeline includes a product candidate targeting choroideremia chm which is in a phase iii clinical trial and a product candidate for hemophilia a which is in a phase iii clinical trial the companys product investigational candidate voretigene neparvovec is intended to treat a genetic blinding condition or inherited retinal disease ird caused by non sexlinked or autosomal recessive biallelic mutations in the rpe gene the company has received orphan product designation for voretigene neparvovec for the treatment of rpemediated ird in both the united states and the european unionthe companys lead product candidate spkchm is indicated for the treatment of chm the company has received orphan product designation for spkchm for the treatment of chm in both the united states and the european union the programs targeting hematologic disorders include spkfix for which the lead product candidate spk is in a phase iii clinical trial for the treatment of hemophilia b in collaboration with pfizer inc as well as spkfviii for the treatment of hemophilia a spk has received both breakthrough therapy and orphan drug designation by the united states food and drug administration fda in its spkfviii program for the treatment of hemophilia a the company has initiated a doseescalating phase iii clinical trial for its lead product candidate spk the company is developing neurodegenerative disease product candidates that are intended to address tripeptidylpeptidase  tpp deficiency which is a form of batten disease and huntingtons disease among others the company has received orphan product designation in the united states for spktpp for the treatment of ceroid lipofuscinosis neuronal  cln disease neuronal ceroid lipofuscinosis ncl caused by tpp deficiency the company has other neurodegenerative disease programs in preclinical developmentthe company competes with bluebird bio inc annapurna therapeutics applied genetic technologies corporation asklepios biopharmaceutical inc audentes therapeutics inc avalanche biotechnologies inc avexis inc abeona therapeutics inc dimension therapeutics inc gensight biologics sa horama sas lysogene sas meiragtx limited nightstarx ltd regenx biosciences llc voyager therapeutics inc second sight medical products inc retina implant ag novelion therapeutics inc nightstarx ltd pfizer inc shire plc sangamo biosciences inc freeline therapeutics biomarin pharmaceutical inc bayer healthcare uniqure nv telethon institute biogen inc alnylam incorporated novo nordisk as and roche holding ag » full overview of onceo company address spark therapeutics inc  market st ste philadelphia   pa    f  company web links home page officers  directors name compensation steven altschuler  katherine high  jeffrey marrazzo  stephen webster  john furey  » more officers  directors spark therapeutics inc news briefspark therapeutics gets rare pediatric disease designation for its investigational treatment from fda jul   brieffda accepts spark therapeuticss application to review luxturna jul   briefselecta biosciences notifies spark therapeutics about license agreement jun   briefspark therapeutics completes rolling biologics license application submission to fda may   briefspark therapeutics reports q loss per share  may   » more onceo news related topics stocksstock screenerhealthcarebiotechnology  medical research investor relations  investors  media  spark therapeutics we arespark our scientific platform  programs« back our scientific platform  programsabout gene therapypatients familieshealthcareprofessionalsinvestors media« backinvestors mediamedia investors overviewstock informationstock quote  charthistorical stock lookupanalyst coverage press releases eventsinvestor presentationscorporate governancecorporate compliancehighlightsofficersboard of directorscommittee compositionfinancial informationsec filingsannual report  proxyshareholder servicesinvestor contactsjoin thespark team investors overview stock informationstock quote  charthistorical stock lookup analyst coveragepress releaseseventsinvestor presentations corporate governancecorporate compliancehighlightsofficersboard of directorscommittee composition financial informationsec filingsannual report  proxy shareholder servicesinvestor contacts print page email page rss feeds email alerts ir contactsinvestor relationsstock informationnasdaq   once common stock change    volume  data as of   pm etrefresh quoterecent news spark therapeutics to host conference call on wednesday aug  at  am et to discuss second quarter  resultsjuly   spark therapeutics receives rare pediatric disease designation for investigational luxturna™ voretigene neparvovec from fdajuly   spark therapeutics’ biologics license application for investigational voretigene neparvovec accepted for filing by fdajuly  read more »upcoming eventsthere are currently no events scheduledread more » data provided by nasdaq minimum  minutes delayed view attributions and sources print page email page rss feeds email alerts ir contactsspark therapeutics inc  market street philadelphia pa  phone sparktx    spark therapeutics inccontact usprivacy policyterms of use spark therapeutics inc career opportunities  jobs  monstercom skip to main content jobs spark therapeutics inc filter results by refinements spark therapeutics inc city philadelphia state pennsylvania industry it executive logistics sales accounting show more education healthcare editorial show less email me jobs get jobs for this search by email well keep looking and send you new jobs that match this search its that simple enter your email address email me jobs by continuing you agree to monsters privacy policy terms of use and use of cookies spark therapeutics inc careers  jobs  spark therapeutics inc jobs found on monster  jobs new applied senior infrastructure engineer spark therapeutics inc philadelphia pa fast apply saved  day ago new applied total rewards lead spark therapeutics inc philadelphia pa fast apply saved  days ago new applied executive administrative assistant  cso spark therapeutics inc philadelphia pa fast apply saved  days ago new applied it infrastructure  operations lead spark therapeutics inc philadelphia pa fast apply saved  days ago new applied internal communications specialist spark therapeutics inc philadelphia pa fast apply saved  days ago new applied supply chain and operations planning lead spark therapeutics inc philadelphia pa fast apply saved  days ago new applied office management lead spark therapeutics inc philadelphia pa fast apply saved  days ago new applied quality control compliance lead spark therapeutics inc philadelphia pa fast apply saved  days ago new applied materials management specialist spark therapeutics inc philadelphia pa fast apply saved  days ago new applied sr search and evaluation associate spark therapeutics inc philadelphia pa fast apply saved  days ago new applied project management lead  it spark therapeutics inc philadelphia pa fast apply saved  days ago new applied pharmacovigilance lead spark therapeutics inc philadelphia pa fast apply saved  days ago new applied environmental health  safety lead spark therapeutics inc philadelphia pa fast apply saved  days ago new applied sr computer systems validation specialist spark therapeutics inc philadelphia pa fast apply saved  days ago new applied senior project manager regulatory spark therapeutics inc philadelphia pa fast apply saved  days ago new applied analytical development associate spark therapeutics inc philadelphia pa fast apply saved  days ago new applied qc analytical sciences scientist spark therapeutics inc philadelphia pa fast apply saved  days ago new applied materials management lead spark therapeutics inc philadelphia pa fast apply saved  days ago new applied logistics and supply chain lead spark therapeutics inc philadelphia pa fast apply saved  days ago new applied talent acquisition operations lead spark therapeutics inc philadelphia pa fast apply saved  days ago get jobs for this search by email well keep looking and send you new jobs that match this search its that simple enter your email address email me jobs by continuing you agree to monsters privacy policy terms of use and use of cookies get jobs for this search by email success your search agent has been saved well keep looking and send you new jobs that match this search its that simple enter your email address email me jobs by continuing you agree to monsters privacy policy terms of use and use of cookies spark therapeutics inc company profile  bloomberg feedback spark therapeutics inc public company company profile sector health care industry biotech  pharma subindustry biotech spark therapeutics inc focuses on the development of gene therapy products the company provides therapy products to transform the lives of patients and reimagine the treatment of debilitating diseases corporate information address  market street philadelphia pa  united states phone  fax  web url wwwsparktxcom board members chairman company steven altschuler university of miami presidentchief scientific ofcrcofounder company ceocofounder company jeffrey marrazzo spark therapeutics inc board members company elliott sigal new enterprise associates inc lars ekman sofinnova ventures inc vincent milano idera pharmaceuticals inc anand mehra sofinnova ventures inc show more from the web once news press releases just how much is a medical miracle worth apr   mystery clot reveals a helpful mutant gene in hunt for a cure apr   pfizer acquires gene therapy firm bamboo for  million aug   spark therapeutics to host conference call on wednesday aug  at  am et to discuss second quarter  results  hours ago spark therapeutics receives rare pediatric disease designation for investigational luxturna™ voretigene neparvovec from fda jul   spark therapeutics’ biologics license application for investigational voretigene neparvovec accepted for filing by fda jul   spark therapeutics announces publication in the lancet of pivotal phase  clinical trial data for investigational voretigene ne jul   spark therapeutics presents updated interim hemophilia b data supporting consistent and sustained response at the international jul   nabriva therapeutics appoints carrie bourdow and colin broom to the board jun   spark therapeutics to present updated hemophilia b data at the international society on thrombosis and haemostasis isth  jun   spark therapeutics to participate in multiple conferences in june jun   key executives jeffrey d marrazzo ceocofounder katherine a high presidentchief scientific ofcrcofounder stephen w webster chief financial officer john p furey chief operating officer j fraser wright ctocofounder daniel r faga chief business officer joseph w la barge joe secygen counselheadbus admin ryan asay headinvestor relations sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data investor relations  investors  media  spark therapeutics we arespark our scientific platform  programs« back our scientific platform  programsabout gene therapypatients familieshealthcareprofessionalsinvestors media« backinvestors mediamedia investors overviewstock informationstock quote  charthistorical stock lookupanalyst coverage press releases eventsinvestor presentationscorporate governancecorporate compliancehighlightsofficersboard of directorscommittee compositionfinancial informationsec filingsannual report  proxyshareholder servicesinvestor contactsjoin thespark team investors overview stock informationstock quote  charthistorical stock lookup analyst coveragepress releaseseventsinvestor presentations corporate governancecorporate compliancehighlightsofficersboard of directorscommittee composition financial informationsec filingsannual report  proxy shareholder servicesinvestor contacts print page email page rss feeds email alerts ir contactsinvestor relationsstock informationnasdaq   once common stock change    volume  data as of   pm etrefresh quoterecent news spark therapeutics to host conference call on wednesday aug  at  am et to discuss second quarter  resultsjuly   spark therapeutics receives rare pediatric disease designation for investigational luxturna™ voretigene neparvovec from fdajuly   spark therapeutics’ biologics license application for investigational voretigene neparvovec accepted for filing by fdajuly  read more »upcoming eventsthere are currently no events scheduledread more » data provided by nasdaq minimum  minutes delayed view attributions and sources print page email page rss feeds email alerts ir contactsspark therapeutics inc  market street philadelphia pa  phone sparktx    spark therapeutics inccontact usprivacy policyterms of use spark therapeutics inc private company information  bloomberg july    pm et biotechnology company overview of spark therapeutics inc snapshot people company overview spark therapeutics inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases its products include voretigene neparvovec which is in phase iii clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sexlinked autosomal recessive or biallelic mutations in the rpe gene and spkchm that is in phase iii clinical trial for the treatment of choroideremia the company’s products also comprise spk that is in phase  trial for choroideremia spk which is in phase  trial for hemophilia b and spk that is in phase  trial hemophilia a in addition its product spark therapeutics inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases its products include voretigene neparvovec which is in phase iii clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sexlinked autosomal recessive or biallelic mutations in the rpe gene and spkchm that is in phase iii clinical trial for the treatment of choroideremia the company’s products also comprise spk that is in phase  trial for choroideremia spk which is in phase  trial for hemophilia b and spk that is in phase  trial hemophilia a in addition its product candidates and development programs include spkfviii program to treat hemophilia a spktpp program for the treatment of a form of batten disease and huntingtons disease rhonova for the treatment of rhodopsinlinked autosomal dominant retinitis pigmentosa and spklhon for treating leber hereditary optic neuropathy as well as preclinical programs in development for the treatment of rare genetic blinding conditions hematologic disorders and other neurodegenerative diseases the company has collaboration agreement with pfizer inc for the development and commercialization of spkfix product candidates in its gene therapy program for the treatment of hemophilia b spark therapeutics inc was founded in  and is headquartered in philadelphia pennsylvania detailed description  market streetsuite philadelphia pa united statesfounded in  employees phone  wwwsparktxcom key executives for spark therapeutics inc mr jeffrey d marrazzo mba mpa cofounder chief executive officer and director age  total annual compensation k dr katherine a high md cofounder president chief scientific officer and director age  total annual compensation k mr stephen w webster chief financial officer age  total annual compensation k mr john furey chief operating officer age  total annual compensation k mr daniel r faga chief business officer age  total annual compensation k compensation as of fiscal year  spark therapeutics inc key developments spark therapeutics receives rare pediatric disease designation for investigational luxturna voretigene neparvovec from fda jul   spark therapeutics  announced that the offices of orphan products development and pediatric therapeutics of the us food and drug administration fda have designated investigational luxturna voretigene neparvovec as a drug for a rare pediatric disease under fdas rare pediatric disease priority review voucher program companies who receive approval for a new drug application or biologics license application bla for a rare pediatric disease may be eligible to receive a voucher for a priority review of a subsequent marketing application for a different product the priority review voucher may be used by the company or sold to a third party fda’s office of tissues and advanced therapies currently is reviewing the bla for luxturna for the treatment of patients with vision loss due to confirmed biallelic rpe mutationassociated retinal dystrophy under a priority review designation with a prescription drug user fee act pdufa action date of jan   luxturna has the potential to be both the first pharmacologic treatment for an inherited retinal disease ird and the first gene therapy for a genetic disease approved in the united states a natural history study has shown that people with this ird eventually progress to complete blindness spark therapeutics inc announces us food and drug administration accepts the filing of biologics license application jul   spark therapeutics inc announced that the us food and drug administration fda has accepted for filing the biologics license application bla and granted priority review for voretigene neparvovec an investigational potential onetime gene therapy candidate for the treatment of patients with vision loss due to confirmed biallelic rpemediated inherited retinal disease ird the investigational gene therapy which has the proposed trade name luxturnatm voretigene neparvovec has the potential to be both the first pharmacologic treatment for ird and the first gene therapy for a genetic disease in the united states priority review is granted to therapeutics that would offer major advances over existing therapies or would provide a treatment where no adequate therapy exists fdas goal for taking an action on priority review applications is six months for the review of luxturna fda has assigned a pdufa date of january   investigational luxturna is intended to be administered one time per eye in patients with vision loss due to biallelic rpemediated ird a natural history study has shown that people with this ird eventually progress to complete blindness luxturna clinical trial overview the safety and efficacy of luxturna were assessed in two openlabel phase  trials which continue to follow participants who received luxturna between  and  and one openlabel randomized controlled phase  trial following the oneyear control period of the phase  study all control participants elected to cross over and received luxturna longterm safety and efficacy continue to be assessed in the phase  participants who received luxturna between  and  the clinical trial program included  participants with vision loss aged four to  at the time of first administration confirmed biallelic rpe mutations and the presence of sufficient viable retinal cells were established in all participants spark therapeutics inc presents at casss’ cmc strategy forum summer  jul  pm jul   spark therapeutics inc presents at casss’ cmc strategy forum summer  jul  pm venue gaithersburg maryland united states speakers diane i blumenthal head of technical operations similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target private placement december   selecta biosciences inc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact spark therapeutics inc please visit wwwsparktxcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close once key statistics  spark therapeutics inc financial ratios  marketwatch bulletin trump tweets he has named john kelly new chief of staff » investor alert new york markets after hours market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close spark therapeutics inc nasdaq once go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus spark therapeutics inc after hours  quotes are delayed by  min jul    pm once quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   company description spark therapeutics inc engages in the research development and commercialization of gene therapies its product portfolio intends to treat inherited retinal sickness livermediated and neurodegenerative diseases the company was founded by jean bennett beverly davidson katherine a high jef spark therapeutics inc engages in the research development and commercialization of gene therapies its product portfolio intends to treat inherited retinal sickness livermediated and neurodegenerative diseases the company was founded by jean bennett beverly davidson katherine a high jeffrey d marrazzo j fraser wright and jennifer wellman on march   and is headquartered in philadelphia pa valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title mr jeffrey d marrazzo   chief executive officer  director mr john furey   chief operating officer mr stephen w webster   cfo  principal accounting officer dr j fraser wrignt   chief technology officer mr daniel r faga   chief business officer insider actions – purchase – sale  – number of transactions  date name shares transaction value  jeffrey d marrazzo chief executive officer director    disposition at  per share   jeffrey d marrazzo chief executive officer director    derivativenonderivative trans at  per share   daniel r faga chief business officer    disposition at  per share   daniel r faga chief business officer    derivativenonderivative trans at  per share   katherine a high see remarks director    disposition at  per share   katherine a high see remarks director    derivativenonderivative trans at  per share   sofinnova ventures inc director    disposition at  per share   jeffrey d marrazzo chief executive officer director    disposition at  per share   jeffrey d marrazzo chief executive officer director    derivativenonderivative trans at  per share   sofinnova ventures inc director    disposition at  per share   jeffrey d marrazzo chief executive officer director    disposition at  per share   jeffrey d marrazzo chief executive officer director    derivativenonderivative trans at  per share   katherine a high see remarks director    disposition at  per share   stephen w webster chief financial officer    disposition at  per share   katherine a high see remarks director    derivativenonderivative trans at  per share   stephen w webster chief financial officer    derivativenonderivative trans at  per share   joseph w la barge general counsel    disposition at  per share   joseph w la barge general counsel    derivativenonderivative trans at  per share   joseph w la barge general counsel    derivativenonderivative trans at  per share   daniel r faga chief business officer    disposition at  per share   daniel r faga chief business officer    derivativenonderivative trans at  per share   the childrens hospital of philadelphia foundation director    disposition at  per share   katherine a high see remarks director    disposition at  per share   katherine a high see remarks director    derivativenonderivative trans at  per share  newslatestcompanyusonce marketwatch news on once these are the  stocks wall street is most afraid of  pm may    ryan vlastelica spark therapeutics started at buy with  stock price target at ubs  pm march    tomi kilgore bull trend confirmed charting the ‘tax reform’ technical breakout  pm feb    michael ashbaugh this is no time for speculators to stay on the sidelines  pm sept    the trading deck sp  returns to the range dow industrials nail first resistance  am aug    michael ashbaugh investors shouldn’t fear this pullback they should embrace it  am aug    the trading deck spark therapeutics started at outperform with  stock price target at rbc capital  am july    tomi kilgore spark therapeutics started at buy with  stock price target at cantor fitzgerald  am june    tomi kilgore is wall street in the middle of a ‘garbage’ stockmarket rally  am feb    mark decambre investors can expect more risk for less reward due to central banks says ray dalio  am feb    barbara kollmeyer some biotechnology stocks that provide ‘clear opportunities’ jp morgan says  pm feb    emma court tune up financial plans from lessons learned in   pm jan    robert stammers surging fitbit races past gopro’s market valuation  am june    mark decambre  stocks to watch  pm april    the trading deck a pair of securitysoftware stocks are in play  pm march    the trading deck newsnonmarketwatchcompanyusonce other news on once biotech fever cools as these players dip on longerterm views  pm july    investors business daily daily insider ratings round up  le tts iff apen skis  am july    seeking alpha premarket analyst action  healthcare  am july    seeking alpha sparks aflyin  pm july    seeking alpha biotech bonanza the next leg up  pm july    seeking alpha value investment stock selections using forensic analysis  july  am july    seeking alpha spark therapeutics once worth a look stock gains   am july    zackscom sparks voretigene neparvovec nabs rare pediatric disease designation from fda  am july    seeking alpha spark therapeutics let the pdufa runup commence  am july    seeking alpha  things in biotech you should learn today july    am july    seeking alpha  things in biotech you should learn today july    am july    seeking alpha spark therapeutics opportunity on positive phase  data  pm july    seeking alpha implied volatility surging for spark therapeutics once stock options  am july    zackscom biotechs gained  billion last week — can they keep going  pm july    investors business daily premarket analyst action  healthcare  am june    seeking alpha spark therapeutics once presents at jefferies  global healthcare conference  slideshow  pm june    seeking alpha spark therapeutics upcoming fda catalyst  pm may    seeking alpha spark therapeutics the next big thing in gene therapy  pm may    seeking alpha sangamos gene therapy gets pfizer stamp of approval  am may    seeking alpha q spark therapeutics inc  pm may    edgar online  edg  q k loading more headlines at a glance spark therapeutics inc  market street suite  philadelphia pennsylvania  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue m net income m employees  annual report for once newspressreleasecompanyusonce press releases on once spark therapeutics to host conference call on wednesday aug  at  am et to discuss second quarter  results  am today am july    globenewswire spark therapeutics receives rare pediatric disease designation for investigational luxturnatm voretigene neparvovec from fda  am july    globenewswire spark therapeutics biologics license application for investigational voretigene neparvovec accepted for filing by fda  am july    globenewswire spark therapeutics announces publication in the lancet of pivotal phase  clinical trial data for investigational voretigene neparvovec  pm july    globenewswire spark therapeutics presents updated interim hemophilia b data supporting consistent and sustained response at the international society on thrombosis and haemostasis isth  congress  am july    globenewswire spark therapeutics to present updated hemophilia b data at the international society on thrombosis and haemostasis isth  congress  am june    globenewswire spark therapeutics to participate in multiple conferences in june  am june    globenewswire spark therapeutics completes rolling biologics license application submission to fda for investigational gene therapy voretigene neparvovec  am may    globenewswire current financing options drug pricing and reimbursement on agenda at association of bioscience financial officers national conference  am may    pr newswire  prf spark therapeutics reports first quarter  financial results and recent business progress  am may    globenewswire spark therapeutics to participate in multiple meetings in may  am may    globenewswire spark therapeutics to host conference call on tuesday may  at  am to discuss q  results  am may    globenewswire spark therapeutics presents updated preliminary data from hemophilia b phase  trial suggesting consistent and sustained levels of factor ix activity at the hemostasis and thrombosis research society htrs  scientific symposium  am april    globenewswire spark therapeutics to present updated hemophilia b data at the hemostasis and thrombosis research society htrs  scientific symposium  pm april    globenewswire spark therapeutics to participate in multiple conferences in march  am march    globenewswire spark therapeutics and pfizer announce that spk an investigational hemophilia b medicine has been granted access to the priority medicines prime program by the european medicines agency  pm march    globenewswire spark therapeutics reports  financial results and business highlights  am feb    globenewswire spark therapeutics to host conference call on wednesday feb  at  am to discuss  results  am feb    globenewswire spark therapeutics to participate in multiple february conferences  am jan    globenewswire spark therapeutics announces us orphan drug designation amendment and study updates for lead investigational gene therapy  am jan    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pbreakingtrump tweets hes named a new chief of staff john kelly pwall street isn’t ready for a point tumble in the dow industrials plongdated treasury yields see weekly climb psp  nasdaq finish lower after amazon disappointment dow closes at record pthe highest paid athletes in the world in one chart phow to raise your kids to be frugal but not too frugal pcities to move to if you want to work in tech — not including san francisco pwhat donald trump’s battle of wills with jeff sessions teaches you about a difficult boss pone way you’re paying creditcard fees even if you don’t have a card ptrump russia and sanctions what we know pthis is the worst mistake people make at work pmove over breathalyzers ‘textalyzers’ could be used on drivers’ phones pjared kushner’s unorthodox approach to meetings is a cautionary tale for office workers everywhere phere’s how much you should spend on a yoga mat p weird things i found out about america in my first  hours pweekend sip is this the world’s first distilled nonalcoholic spirit pgoodyear stock stumbles  after quarter ‘played out differently than we expected’ ptime for gop to face reality everybody is going to have health insurance pbreakingdow industrials just  points shy of  milestone pwhy tax cuts for the rich solve nothing loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft spark therapeutics inc  ipo candy skip to primary navigation skip to content becomeamember ipo candyeveryones favorite site for ipo insights and analysismain navigationhome » spark therapeutics incspark therapeutics inc  by spark therapeutics inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases the company is developing spkrpe which is in phase iii clinical trial for the treatment of inherited retinal dystrophies a group of rare blinding conditions caused by nonsex linked or autosomal recessive mutations in the rpe gene it is also developing spkchm for the treatment of choroideremia and preclinical programs in development for the treatment of hemophilia a and neurodegenerative diseases as well as a pipeline of product candidates targeting rare blinding conditions the company has collaboration agreement with pfizer inc for the development and commercialization of spkfix product candidates in its gene therapy program for the treatment of hemophilia b spark therapeutics inc was founded in  and is based in philadelphia pennsylvania spark therapeutics inc spark therapeutics inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases the company is developing spkrpe which is in phase iii clinical trial for the treatment of inherited retinal dystrophies a group of rare blinding conditions caused by nonsex linked or autosomal recessive mutations in the rpe gene it is also developing spkchm for the treatment of choroideremia and preclinical programs in development for the treatment of hemophilia a and neurodegenerative diseases as well as a pipeline of product candidates targeting rare blinding conditions the company has collaboration agreement with pfizer inc for the development and commercialization of spkfix product candidates in its gene therapy program for the treatment of hemophilia b spark therapeutics inc was founded in  and is based in philadelphia pennsylvania twitter facebook google linkedin spark therapeutics incpspark therapeutics inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases the company is developing spkrpe which is in phase iii clinical trial for the treatment of inherited retinal dystrophies a group of rare blinding conditions caused by nonsex linked or autosomal recessive mutations in the rpe gene it is also developing spkchm for the treatment of choroideremia and preclinical programs in development for the treatment of hemophilia a and neurodegenerative diseases as well as a pipeline of product candidates targeting rare blinding conditions the company has collaboration agreement with pfizer inc for the development and commercialization of spkfix product candidates in its gene therapy program for the treatment of hemophilia b spark therapeutics inc was founded in  and is based in philadelphia pennsylvaniap paunited statesphone  once treatments for genetic diseases documents roadshow main categoryhealthcare categoriesdrugs contact httpwwwsparktxcom  address market street suite  philadelphia pennsylvania  united states we love ipos the ipo market provides a magical window into the most exciting technologies emerging consumer trends and important business developments  all testing their mettle in the crucible of the public markets we are constantly learning and researching to deliver the best insights available we are independent we have no vested interests driving our work all the investment banks and brokers on a deal are paid to do a sales and marketing job our job is to remain objective and use a factbased approach to evaluate the potential for an ipo we get the best ratings ipo candy has been recognized since  as the single best place to get commentary analysis and assets in the ipo market the most common writein comment we get from users is that they love what we do we share everything we know with three decades of research under our belt we want to share what we have learned and the best practices we have discovered our ipo university contains texts videos and resources to share our process and help everyone develop their skills become an ipocandy member enjoy the benefits of full access to our content including access to ipo roadshow slideshows and transcripts included in our posts members also get additional insights via email receive our monthly candygram and have access to our ipo calendar become a member spark therapeutics we arespark our scientificplatform  programs « back our scientificplatform  programs about gene therapy patients families healthcareprofessionals investors media « back investors media media investors overview stock information stock quote  chart historical stock lookup stock calculator analyst coverage press releases events investor presentations corporate governance corporate compliance highlights management team board of directors committee composition annual meeting financial information sec filings shareholder services investor contacts join thespark team we don’t follow footstepswe create the path alyssa living with leber congenital amaurosis due to mutations in the rpe gene with her dad ken news  events bla filing acceptancespark therapeutics announces fda acceptance of bla for filing with priority review of investigational gene therapy luxturna™ voretigene neparvovec read more data published in the lancetspark therapeutics announces publication in the lancet of pivotal phase  data at year one for investigational voretigene neparvovec read more isth spark therapeutics presents updated interim hemophilia b data supporting consistent and sustained response at the isth  congress read more “mits  smartest companies”spark therapeutics has been named to mit technology reviews  smartest companies list in the top  for the second year in a row read more all news  media we don’t follow footsteps we create the pathour mission at spark therapeutics is to challenge the inevitability of genetic disease by discovering developing and delivering potential treatments in ways unimaginable—until now we have built a fully integrated company combining our proprietary adenoassociated viral aav gene therapy platform with excellence in rd manufacturing and commercial operations find out more about how we strive to turn genes into medicines for patients with inherited diseases including inherited retinal diseases irds livermediated diseases such as hemophilia and neurodegenerative diseases cuttingedge vector design stateoftheart inhouse expertise in vector manufacturing innovative scientific and regulatory strategies strong commitment to improve patient care learn more spark therapeutics inc  market street philadelphia pa  phone sparktx      spark therapeutics inc contact us privacy policy terms of use investor relations  investors  media  spark therapeutics we arespark our scientific platform  programs« back our scientific platform  programsabout gene therapypatients familieshealthcareprofessionalsinvestors media« backinvestors mediamedia investors overviewstock informationstock quote  charthistorical stock lookupanalyst coverage press releases eventsinvestor presentationscorporate governancecorporate compliancehighlightsofficersboard of directorscommittee compositionfinancial informationsec filingsannual report  proxyshareholder servicesinvestor contactsjoin thespark team investors overview stock informationstock quote  charthistorical stock lookup analyst coveragepress releaseseventsinvestor presentations corporate governancecorporate compliancehighlightsofficersboard of directorscommittee composition financial informationsec filingsannual report  proxy shareholder servicesinvestor contacts print page email page rss feeds email alerts ir contactsinvestor relationsstock informationnasdaq   once common stock change    volume  data as of   pm etrefresh quoterecent news spark therapeutics to host conference call on wednesday aug  at  am et to discuss second quarter  resultsjuly   spark therapeutics receives rare pediatric disease designation for investigational luxturna™ voretigene neparvovec from fdajuly   spark therapeutics’ biologics license application for investigational voretigene neparvovec accepted for filing by fdajuly  read more »upcoming eventsthere are currently no events scheduledread more » data provided by nasdaq minimum  minutes delayed view attributions and sources print page email page rss feeds email alerts ir contactsspark therapeutics inc  market street philadelphia pa  phone sparktx    spark therapeutics inccontact usprivacy policyterms of use